The South & Central America malaria treatment market was valued at US$ 59.68 million in 2022 and is expected to reach US$ 247.33 million by 2030; it is estimated to grow at a CAGR of 19.4% from 2022 to 2030.
Growing Strategic Initiatives by Market Players Drive South & Central America Malaria Treatment Market
A few major players operating in the malaria treatment market are increasingly focusing on the adoption of various strategies such as product innovations, launches, and approvals; R&D investments; and mergers and acquisitions in order to remain competitive. A few of these initiatives are mentioned below:
Therefore, the abovementioned strategic initiatives by the market players are expected to provide growth opportunities for the malaria treatment market in the coming years.
South & Central America Malaria Treatment Market Overview
Malaria has always been a major public health concern in Brazil. According to an article by NCBI, in Brazil, malaria is caused by three species of Plasmodium, P. vivax (accounts for 83.7% of the registered cases), P. falciparum (causes 16.3% of the cases), and P. malariae (records a small proportion of cases).
The government of Brazil launched the National Malaria Elimination Plan, which aims to reduce the number of local malaria cases to less than 68,000 by 2025 and eliminate associated deaths by 2030, as well as eradicate the disease in the country by 2035. Brazil houses the Amazon rainforest, which records the majority of malaria cases. Approximately 99.9% of transmissions in Brazil occur in the Amazon region and 80% in 33 cities. According to the WHO World Malaria 2020 Report, in Brazil, ~2,00,000 cases have been registered in the country in recent years; approximately 99% of these cases were concentrated in Legal Amazon. The government of Brazil is investing in treatment development, pest control, and technical support while also providing training personnel. The Brazilian Unified Health System adopted the National Malaria Elimination Plan, which offers free diagnosis and treatment, takes decentralized actions for diagnostic and wide coverage treatment, and adopts online information systems, multi-sector partnerships, and research networks. On October 30, 2019, GSK Brazil and MMV announced that the Brazilian Health Regulatory Agency (AVINSA) had granted the Marketing Authorization Approval under propriety review for the single-dose tafenoquine for the treatment of acute P. vivax malarial infection in patients aged 16 and above older, who are already receiving chloroquine as medication. Jose Carlos Felner, the president of the GSK's pharmaceutical division in Brazil, stated that the approval of tafenoquine in the country is an important step in the fight against neglected diseases such as malaria. The introduction of novel antimalarial drugs is increasing the demand for malaria treatment in Brazil, thereby helping authorities accomplish the goal of eradicating the disease.
South & Central America Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)
Strategic insights for the South & Central America Malaria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the South & Central America Malaria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.South & Central America Malaria Treatment Strategic Insights
South & Central America Malaria Treatment Report Scope
Report Attribute
Details
Market size in 2022
US$ 59.68 Million
Market Size by 2030
US$ 247.33 Million
Global CAGR (2022 - 2030)
19.4%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Treatment
By Route of Administration
By Distribution Channel
Regions and Countries Covered
South and Central America
Market leaders and key company profiles
South & Central America Malaria Treatment Regional Insights
South & Central America Malaria Treatment Market Segmentation
The South & Central America malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the South & Central America malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest market share in 2022.
In terms of route of administration, the South & Central America malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022.
By distribution channel, the South & Central America malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.
Based on country, the South & Central America malaria treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America malaria treatment market share in 2022.
Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd are some of the leading players operating in the South & Central America malaria treatment market.
1. Cipla Ltd
2. Sun Pharmaceutical Industries Ltd
3. Sanofi SA
4. GSK Plc
5. Novartis AG
6. Pfizer Inc
7. Lupin Ltd
The South & Central America Malaria Treatment Market is valued at US$ 59.68 Million in 2022, it is projected to reach US$ 247.33 Million by 2030.
As per our report South & Central America Malaria Treatment Market, the market size is valued at US$ 59.68 Million in 2022, projecting it to reach US$ 247.33 Million by 2030. This translates to a CAGR of approximately 19.4% during the forecast period.
The South & Central America Malaria Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Malaria Treatment Market report:
The South & Central America Malaria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Malaria Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Malaria Treatment Market value chain can benefit from the information contained in a comprehensive market report.